The origin of these latter disturbances is undoubtedly complex and multifactorial, but there is good evidence that a component of this phenomenon is an altered responsiveness of the ACTH receptor ...

A number of potential targets exist for medical therapy including inhibition of steroidogenesis, inhibition of ACTH secretion and glucocorticoid receptor antagonism (Table 1). The most commonly ...

“There has been a long-standing interest in using a potent, selective antagonist of the ACTH receptor for the treatment of CAH and other diseases of ACTH excess, leading to the design of ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH) study of investigational ...

She started her MRC funded postdoctoral fellowship with Prof. Clark in 2007 to further the work carried out on the ACTH receptor and MRAP. She was awarded the Outstanding Young Investigator awards at ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH ...

[51] ACTH: Adrenocorticotrophic hormone ... for improvement in glucose control is desirable. Glucocorticoid receptor antagonists (mifepristone) and somatostatin receptor antagonists (pasireotide ...

"There has been a long-standing interest in using a potent, selective antagonist of the ACTH receptor for the treatment of CAH and other diseases of ACTH excess, leading to the design of atumelnant by ...